Vedolizumab as a first-line biologic for Crohn's?

Trial shows patients with severe disease can achieve remission

About one patient in eight experiences endoscopic remission of Crohn's disease after completing 26 weeks of treatment with the gut-selective monoclonal antibody vedolizumab, a study shows.